TCRβ repertoire, frequencies of newly emerging T-cell clones, and CCR4 and FOXP3 expression in PBMCs after mogamulizumab or chemotherapy. (A) ISDI for the TCRβ repertoire in PBMCs after mogamulizumab treatment in patients with (n = 16) or without (n = 8) EM, as well as after chemotherapy without mogamulizumab (n = 11). (B) Frequencies of newly emerging T-cell clones after mogamulizumab in patients with (n = 16) or without (n = 8) EM, as well as after chemotherapy (n = 11). CCR4 (C) and FOXP3 (D) expression in PBMCs after mogamulizumab in patients with (n = 16) or without (n = 8) EM.